Pennington Biomedical Research Center, Baton Rouge, LA, USA.
Eli Lilly and Company, Indianapolis, IN, USA.
Drug Discov Today. 2018 Feb;23(2):333-348. doi: 10.1016/j.drudis.2017.11.012. Epub 2017 Nov 15.
Functional magnetic resonance imaging (fMRI) has been known for over a decade to have the potential to greatly enhance the process of developing novel therapeutic drugs for prevalent health conditions. However, the use of fMRI in drug development continues to be relatively limited because of a variety of technical, biological, and strategic barriers that continue to limit progress. Here, we briefly review the roles that fMRI can have in the drug development process and the requirements it must meet to be useful in this setting. We then provide an update on our current understanding of the strengths and limitations of fMRI as a tool for drug developers and recommend activities to enhance its utility.
功能性磁共振成像（fMRI）十多年来一直被认为具有极大的潜力，可以极大地促进开发治疗常见健康状况的新型治疗药物的进程。然而，由于各种技术、生物和战略障碍继续限制进展，fMRI 在药物开发中的应用仍然相对有限。在这里，我们简要回顾 fMRI 在药物开发过程中可以发挥的作用，以及它在这种情况下必须满足的要求。然后，我们提供了当前对 fMRI 作为药物开发人员工具的优势和局限性的理解的更新，并建议了增强其效用的活动。
